Roche’s RoACTEMRA Approved in Europe for Children Living With a Rare, Severe Form of Arthritis

Roche announced that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
4-Traders